Quick Links

Accreditation/Credit Designation

Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians' Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.5 Contact Hours.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from AstraZeneca.

Community Practice Connections™: PARP Inhibition in Breast Cancer: Practical Methods to Interpret and Apply the Evidence for Your Patients

Release Date: August 30, 2018
Expiration Date: August 30, 2019
Media: Internet - based

Activity Overview

A great deal of progress has been made in the understanding of the mechanistic underpinnings for the use of poly(adenosine diphosphate–ribose) polymerase (PARP) inhibitor therapy in the treatment of patients with breast cancer. As the volume of evidence supporting the role of PARP inhibitors continues to accumulate, it is important for you to be able to apply clinical data to the development of treatment paradigms that maximize outcomes for your patients. This includes efficacy considerations, as well as development of strategies to identify and mitigate predictable treatment-related adverse events in a timely fashion.
To help you optimize the management of your patients with breast cancer, we have developed an exciting educational activity that will highlight the latest clinical evidence pertaining to the use of PARP inhibitors. This activity features commentary from leading experts in the management of patients with breast cancer, who will provide their perspectives on the rationale for PARP inhibitor utilization, key aspects of recent clinical studies, strategies to mitigate and manage predictable adverse events, and future directions for PARP inhibitor therapy.

Instructions for This Activity and Receiving Credit

  • You will need to login to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review videos/content until you finish the presentation.
  • At the end of the activity, “educational content/video files” will be available for your reference.
  • In order to receive a CME/CE certificate, participants must complete the activity.
  • Complete the posttest and pass with a score of 70% or higher, complete the evaluation and then click on request for credit. Participants may immediately download a CME/CE certificate upon completion of these steps.

Target Audience

This educational activity is directed toward medical oncologists who treat patients with breast cancer. Nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other healthcare professionals interested in the treatment of breast cancer are also invited to participate.

Learning Objectives

At the conclusion of this activity, you should be better prepared to:

  • Outline the mechanistic rationale that underlies the application of poly(adenosine diphosphate–ribose) polymerase (PARP) inhibition approaches for the management of breast cancer
  • Apply key evidence from PARP inhibition trials in breast cancer, and report recent findings from investigations evaluating potential new roles for these approaches
  • Summarize strategies to mitigate predictable toxicities that have been reported with the use of PARP inhibition strategies
  • Identify strategies that are being explored to maximize the efficacy of PARP inhibition in the treatment of patients with breast cancer

Faculty, Staff, and Planners' Disclosure

Susan M. Domchek, MD
Director, MacDonald Women’s Cancer Risk Evaluation Center
Executive Director, Basser Center for BRCA
Basser Professor in Oncology
Perelman School of Medicine
University of Pennsylvania
Philadelphia, PA

Disclosure: Other: Honoraria: AstraZeneca, Clovis Oncology, Bristol-Myers Squibb.

Sara A. Hurvitz, MD
Associate Professor of Medicine, Division of Hematology/Oncology
Director, Breast Cancer Clinical Research Program
Co-Director, Santa Monica–UCLA Outpatient Hematology/Oncology Practice
David Geffen School of Medicine at UCLA
Santa Monica, CA

Disclosure: Grant Research Support: Amgen, Bayer, BI Pharma, Genentech, GlaxoSmithKline, Lilly, Novartis, Pfizer, Roche, Puma Biotechnology, Merrimack Pharmaceuticals, Medivation, Dignitana, OBI Pharma, BioMarin, Cascadian Therapeutics; Other: Travel Support: Lilly, Novartis, OBI Pharma, Bayer.

Mark E. Robson, MD
Chief, Breast Medicine Service
Attending Physician, Breast Medicine and Clinical Genetics Services
Professor of Medicine, Weill Cornell Medical College
Memorial Sloan Kettering Cancer Center
New York, NY

Disclosure: Grant Research Support: AstraZeneca, AbbVie, Myriad Genetics, Medivation, Invitae; Consultant: AstraZeneca, McKesson.

Melinda L. Telli, MD
Assistant Professor of Medicine in the Division of Medical Oncology
Stanford University School of Medicine
Stanford, CA

Disclosure: Consultant: Celldex Therapeutics, G1 Therapeutics, Immunomedics, Merck, Pfizer, PharmaMar, Tesaro.

The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.
Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME/CE activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician or nurse relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.

Become a Member

Forgot Password?
Calendar of Events
Filter By